December 16, 2020
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 23 million. SiB Solutions offers a software for video content analytics that provides efficient monitoring and analysis of logistics processes to minimize shrinkage in the supply chain. The value of goods lost in logistics processes globally is estimated at around EUR 10 billion each month, with consequential costs of around EUR 20 billion.
» Read moreNovember 23, 2020
Vator Securities agerar som finansiell rådgivare i samband med transaktionen om SEK 37 miljoner. Xintela är en innovatör i utvecklingen avregenerativa cellterapier och riktade cancerterapier baserade på denpatenterade markörteknologiplattformen XINMARK®.
» Read moreNovember 20, 2020
Vator Securities acts as Financial Adviser in connection with the transaction raising approximately SEK 150 million. NextCell is a cell therapy company that has recently finished phase II with its leading drug candidate, ProTrans™, a treatment for type 1 diabetes. In the Company's clinical trials, ProTrans™ has demonstrated both safety and efficacy regarding the patient's own preservation of insulin production.
» Read moreNovember 16, 2020
Vator Securities acts as Financial Adviser in connection with the transaction raising approximately SEK 236 million. Scandion Oncology is a clinical phase II biotechnology company addressing cancer drug resistance as a complement to existing anti-cancer therapies by developing first-in-class, oral add-on drugs. Used as a combination therapy, the Company’s products have the potential to quickly reach peak sales in addition to potentially offering better response rates and increased survival time with improved quality of life.
» Read moreNovember 6, 2020
Vator Securities acts as Financial Adviser in connection with the transaction raising approximately SEK 150 million. Moberg Pharma is a Specialty Pharma company focused on developing and commercialising proprietary, acquired and licensed products globally, from clinical development of products based on proven substances to commercialisation.
» Read moreOctober 26, 2020
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 110 million. The SEK 110 million in growth capital was raised from institutional and private investors in Sweden to fund the commercialization of Stockholm3, A3P’s superior prostate cancer test.
» Read moreOctober 21, 2020
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 32 million. SciBase AB is a Swedish medical technology company, headquartered in Stockholm, that has developed a unique point of care device for the accurate detection of malignant melanoma.
» Read moreJune 12, 2020
Vator Securities agerar som finansiell rådgivare i samband med transaktionen om SEK 40,5 miljoner. Xintela är en innovatör i utvecklingen avregenerativa cellterapier och riktade cancerterapier baserade på denpatenterade markörteknologiplattformen XINMARK®.
» Read moreJune 11, 2020
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 59,3 million. LIDDS is a Swedish-based pharmaceutical company which develops new innovative pharmaceutical products with its proprietary drug delivery technology NanoZolid®.
» Read moreJune 4, 2020
Vator Securities acted as Joint Bookrunner in connection with the transaction raising SEK 400 million. Vator Securities was involved in more than two-third of the final allocations to local and international specialist investors, thereby strongly delivering upon the company’s goal to diversify its shareholder base.
» Read moreMay 20, 2020
Vator Securities acted as Global Coordinator and Sole Bookrunner in connection with the transaction raising SEK 146million. The Directed Share Issue was directed to selected Swedish and international institutional investors, among others, TIN Fonder, Swedbank Robur Ny Teknik and current shareholders Swedbank Robur Medica, STADA Arzneimittel and Serendipity Group among others.
» Read moreMay 15, 2020
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 25 million. NextCell is a cell therapy company with its leading drug candidate, ProTrans™, a treatment for type 1 diabetes, in a clinical phase II.
» Read moreMay 6, 2020
Swiss Nordic Bio 2020 was held on 6 February in Zurich and was a collaboration between Vator Securities, the Embassy of Sweden, the Norwegian Embassy, Business Sweden and Business Finland. Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet. Here you will find the film from the event.
» Read moreMarch 27, 2020
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 25 million. The capital raised in the rights issue will primarily be used to increase the market presence and penetration of SciBase in the US market where an FDA approval of Nevisense 3.0 is expected during the second quarter of 2020.
» Read moreFebruary 3, 2020
Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet. Swiss Nordic Bio 2020 will be held on 6 February in Zurich and is a collaboration between Vator Securities, the Embassy of Sweden, the Norwegian Embassy, Business Sweden and Business Finland.
» Read more